In addition, chemically modified MIR143 (MIR143#12) anticancer effects involve inhibition of KRAS networks in pancreatic cancer cells with/without KRAS mutation and exhibit high-level RNA nucleases resistance activity [4,65]. The gene discussed is KRAS; the disease is pancreatic neoplasm.